2021
The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effects
2017
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Berger E, Johannes C, Post G, Rothchild G, Shiu K, Wetzel S, Fox L. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal Of Feline Medicine And Surgery 2017, 20: 95-102. PMID: 29172873, PMCID: PMC11129263, DOI: 10.1177/1098612x17695898.Peer-Reviewed Original ResearchConceptsMast cell neoplasiaCell neoplasiaAdverse eventsClinical benefitUse of toceranibDuration of therapyPossible clinical benefitFurther prospective studiesMajority of catsVeterinary Internal MedicineHematologic eventsToceranib treatmentGastrointestinal involvementMedian doseMedian durationDose adjustmentTreatment breaksProspective studyConcurrent treatmentAmerican CollegeRetrospective evaluationAnatomic classificationFeline patientsGastrointestinal casesToceranib